Literature DB >> 29936711

Exploring the Causes of the Low Incidence of Cervical Cancer in Western Asia

Ghazi Alsbeih1.   

Abstract

Anecdotal epidemiologic observations can provide valuable tools to study various biologic elements in complex diseases such as cancer. Although cervical cancer is one of the most frequent malignancy affecting women in the world, it displays wide geographical variations remnant of socioeconomic, ethnic and genetic predisposing factors. The observed low incidence of cervical cancer in western Asia has triggered scientists to try to delineate the causes of this reduced occurrence. Although this region including Saudi Arabia is known for being conservative societies with low incidence of sexually transmitted infections including human papillomavirus (HPV) and associated cervical cancer, scientific research points out multifaceted biological explanations including host genetic variations. Researchers observed that a protective genetic variant TP53 codon 72 proline allele was more commonly found in this population and appear to be over-transmitted compared to others known for their high rate of cervical cancer. Thus, the combination of relative low rate of HPV infection, over-transmission of protective genetic variant along with societal variables are the rationale behind the low incidence of cervical cancer in women in the region of western Asia. The influence of the genetic makeup of the patients has impact on personalized preventive medicine to gauge the risk of developing cervical cancer. Creative Commons Attribution License

Entities:  

Keywords:  Cervical cancer; human papillomavirus (HPV); TP53 polymorphism; cancer predisposition; Western Asia

Mesh:

Year:  2018        PMID: 29936711      PMCID: PMC6103560          DOI: 10.22034/APJCP.2018.19.6.1425

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


Introduction

Cancer of the uterine cervix is mainly a human papillomavirus (HPV) driven disease with an estimated overall involvement rate ranging between 85% and 99% worldwide (zur Hausen, 1991; Walboomers et al., 1999; de Sanjose et al., 2010). HPVs are groups of DNA-viruses that affect skin and moist membranes in the body. The contamination is asymptomatic and the virus is primarily transferred by direct contact between infected skin to skin or to mucous membranes. Currently there are about 120 HPV genotypes that infect human with around 40 types that affect the genital area. High risk HPV genotypes are the primary cause of cervical cancer and the incidence of this tumor is regarded as a surrogate marker for HPV infection particularly in countries lacking epidemiological studies (Alsbeih, 2014). The high risk HPV 16, 18, 31, 52, and 58 are consistently found among the 10 most common genotypes detected in cervical cancer. Infection with HPV is very common during the active sexual life and it does not elicit any immediate signs until persistent infection develops to pre-cancerous lesions years later (Baseman and Koutsky, 2005; Howell-Jones et al., 2012). Immune system clear the infection in most cases with less than 1% of infected women eventually develop invasive cervical cancer (Wang et al., 2010). The global HPV prevalence in women with normal cervical cytological findings is estimated at 11.7% with marked variability across world regions where Sub-Saharan Africa (24.0%), Eastern Europe (21.4%), and Latin America (16.1%) showed the highest rates (Bruni et al., 2010). Asia is a large continent and shows wide variations in reported HPV prevalence in large community-based studies ranging from as low as 7.2% in multiethnic Malaysia to 20.54% in China (Chen et al., 2017; Khoo et al., 2017). In addition, the prevalence displays age-specific HPV distribution with a first peak at younger ages (≤25 years) and a rebound at older ages (≥45 years). These figures represent the most comprehensive assessment of HPV burden among women with normal cytological findings in the pre-HPV vaccination era worldwide. The turning points in prevention of HPV-associated cancer risk are cytological screening for precancerous lesions, molecular screening for high-risk HPV infection and the availability of vaccines against the most common HPV genotypes currently in use in many developed countries. In contrast, basic health care is often lacking in disadvantaged populations such as in resource-limited countries, marginalized and immigrants due to shortage of point-of-care access and the complexities of social and economic situations (Alsbeih, 2015). As a result, there is a tremendous disparity in health consequences for HPV-infected people, as compared to advantaged populations. Thus, healthcare authorities should be more aware of this global cancer disparities.

Geographical variations in cervical cancer

Cervical cancer remains one of the most frequent malignancy affecting women in the world next to breast, colorectal and lung cancers (Ferlay et al., 2015). According to global cancer statistics, there are more than half a million new cases being diagnosed every year and claims the lives of more than a quarter million women (Bray et al., 2013). However, cervical cancer incidence is not uniform in various populations having different socioeconomic and development levels. While cervical swap screening, and HPV vaccinations are helping in reducing precancerous and invasive cases in developed countries, a large majority of the global burden occurs in less-developed regions lacking access to healthcare (Shrestha et al., 2018). About 8 out of 10 cervical cancer deaths occur in low/middle-income countries, particularly in Africa, South America, and parts of Asia, which are the toughest struck by this inequality of mostly a preventable cancer (Bray et al., 2017). Yet, a few geographical regions in the world, such as western Asia (Figure 1), shows unexplainably low cervical cancer incidence despite the lack of proactive national screening or vaccination programs (Al Moustafa et al., 2014; Al-Hammadi et al., 2017). This area of the world is composed of many countries with no definitive number due to geopolitical and economic considerations. Numerous countries are establishing national cancer registries for providing accurate population-based incidence data in order to efficiently allocate healthcare funds and prioritize screening and prevention (Mohagheghi et al., 2009; Ismail et al., 2013; Ibrahim et al., 2014; Badar et al., 2016; Bazarbashi et al., 2017). However, access to specific data in these registries is not always easy and publically reported cancer incidence rates are extracted from the database of the International Agency for Research on Cancer (IARC; an intergovernmental cancer specialized agency of the World Health Organization). These are based on projections using historic/recent cancer registries data of various quality and population coverage rather than actual number of cases (Bazarbashi et al., 2017). Table 1 lists the most up-to-date estimates of cervical cancer incidence in the western Asian countries including Egypt. The estimated age-standardized rates (ASR) of incidence ranges between 2 and 9.5 with an average of 3, which is below the worldwide mean of 7.9 per 100,000 person-year. Being in the middle of this western Asia region, we have used this paradigm to study the rationale behind this low rate of cervical cancer occurrence in Saudi Arabia. Of course, the conservative society, sexual mores and the widely practiced male circumcision are known to play a role in reducing sexually transmitted diseases (STD) including HPV infections, and lessen the frequency of related diseases and potential long-term consequences such as cervical cancer (Filemban et al., 2015). However, these hard-to-measure factors fall short of providing a definitive answer especially that some other geographical areas with similar societal variables show higher incidence (Al-Harbi et al., 2017).
Figure 1

Estimated Age-standardized Rates of Incident Cases of Cervical Cancer in the world according to the most Recent Statistics available to GLOBOCAN 2012. Note that western Asia region displays some of the lowest incidence worldwide. Source: Cancer Today, World Health Organization (http://gco.iarc.fr/today/home).

Table 1

Estimated Number of Cases of Cervical Cancer, Crude and Age-standardized Rates (ASR) in Western Asian Countries Including Egypt in 2012

CountryNumber of casesCrude rateASR
Bahrain224.35.9
Egypt8662.12.3
Iran9472.52.8
Iraq2911.72.8
Israel2035.24.6
Jordan501.62.4
Kuwait302.64
Lebanon1135.14.6
Oman383.25.3
Qatar153.25.1
Saudi Arabia2411.92.7
Syrian Arab Republic21022.6
Turkey16864.54.3
United Arab Emirates933.79.5
West Bank and Gaza Strip2212
Yemen1981.63.1
Western Asia*44553
Worldwide5276247.9

Western Asian countries as defined by IARC-WHO, Source; IARC Cancer Today, World Health Organization (http://gco.iarc.fr/today/home)

Estimated Number of Cases of Cervical Cancer, Crude and Age-standardized Rates (ASR) in Western Asian Countries Including Egypt in 2012 Western Asian countries as defined by IARC-WHO, Source; IARC Cancer Today, World Health Organization (http://gco.iarc.fr/today/home) Estimated Age-standardized Rates of Incident Cases of Cervical Cancer in the world according to the most Recent Statistics available to GLOBOCAN 2012. Note that western Asia region displays some of the lowest incidence worldwide. Source: Cancer Today, World Health Organization (http://gco.iarc.fr/today/home).

Causes of low incidence of cervical cancer in Western Asia

To gain insight into the causes of the low incidence of cervical cancer in western Asia, our research team has looked at the rate of HPV infection and the association with potential polymorphic genetic variables in the population that may contribute to the low incidence of this malignancy in Saudi Arabia (Alsbeih et al., 2017). We have collected 232 samples and demographic data from patients treated for invasive cervical cancers. Interestingly, results showed that in dissimilarity with many other cancers in adults that show maximum occurrence at certain age, cervical cancer displayed two peaks of increased incidence at 43 and 61 years of age (Figure 2). This phenomenon was explained by a combination of conjugal behavior and natural progression of HPV infections. As cancer development takes years to decades to take place, the first peak would be consequent to early sexual encounters which often occurs at the end of teenage period to early thirties, while the 2nd relative rebound corresponds to new encounters later in life. The latter is generally occasioned by separation, failure of 1st marriage as portion of households get into divorce, or simply 2nd marriages in polygamous societies, which brings in an added risk of HPV infections as the number of lifetime sexual partners increases.
Figure 2

Distribution of Cervical Cancer Frequency Showing the Bimodal Curve of Age-specific Occurrence. A first peak is observed at younger ages (43 years) and a relative rebound at older ages (61 years). These highpoints are shifted 5 to 15 years after primary HPV infection, which may represent the time of cervical malignant transformation to take place with probable variation between populations remnant of possible genetic and socio-cultural differences.

Distribution of Cervical Cancer Frequency Showing the Bimodal Curve of Age-specific Occurrence. A first peak is observed at younger ages (43 years) and a relative rebound at older ages (61 years). These highpoints are shifted 5 to 15 years after primary HPV infection, which may represent the time of cervical malignant transformation to take place with probable variation between populations remnant of possible genetic and socio-cultural differences. Looking into the rate of HPV infection in cancer samples, we found relatively lower rate (77%) of infection compared to worldwide estimate (85-99%). Similar results were obtained in neighboring country in western Asia with similar socioeconomic composition (Khorasanizadeh et al., 2013). This low incidence of HPV infection rate provided a 1st element of answer, however; it is not enough to explain the very low rate of cervical cancer (2.1 per 100,000 women) in the population (Bazarbashi et al., 2017). In addition, the distribution of various HPV genotypes were comparable to those found in many other populations. Furthermore, these results do not seem to be due to low prevalence of primary HPV infection in cervical swaps of women attending routine gynecologic clinics (Alhamlan et al., 2015). Therefore, our research team has looked into the pivotal gene encoding the tumor suppressor protein p53 (TP53) which is the most widely evoked candidate gene with potential of modulating cancer predisposition (Lane, 1992). A common genetic variant (G/C, rs1042522) that codes for either arginine (Arg) or proline (Pro) amino-acids in position 72 of p53 protein has longtime suspected to affect the oncogenic potential of the viral HPV-E6 protein (Storey et al., 1998). This single nucleotide polymorphism (SNP) was largely studied in relation to many cancer sites (Stracquadanio et al., 2016), and in various populations but rarely in cervical cancer in western Asia (Alsbeih et al., 2017). The majority Arg form is supposed to favor HPV infection and predispose to cervical cancer as it is more susceptible than the Pro variant to HPV-E6–mediated degradation. Surprisingly, the study found no difference between cancer patients and a matched control group of 313 women without cancer. In front of this dilemma, the team has reanalyzed the data in cancer patients alone by comparing HPV-positive to HPV-negative cases. Interestingly, we found significant association where cancer patients displayed higher frequency of the Arg risk allele in the HPV-positive patients (Odds Ratio, 0.57; 95% confidence interval, 0.36-0.90; P = 0.016). Thus, the study suggests that the TP53 genetic variant is only matter when patients are infected with HPV. In the absence of the infection, the TP53 G72C genetic predisposing factor does not play a role in cervical cancer transformation. Thus, the combination of HPV infection and having the TP53 arginine form in the host genetic composition, constitute a risk factor toward developing cervical cancer. Furthermore, the protective variant Pro allele was significantly over-transmitted in the population (P < 0.0003) which lends support to the low incidence of this HPV-related cancer in Saudi Arabia. In conclusion, anecdotal epidemiologic observations can provide valuable tools to study medical conditions and to better understand the roles of various elements in multifactorial diseases such as cancer. The low incidence of cervical cancer in the specific region of western Asia has triggered researchers to try to understand the causes of this reduced occurrence. Although the laymen would be satisfied with the overall image of conservative society to explain the low incidence of sexually transmitted HPV infection and associated cervical cancer, scientific research points out multifaceted biological explanations including genetic variations. Going back to the initial question on why cervical cancer rate is low in this particular population, the observation that the protective genetic variant TP53 72 proline allele was more commonly found in this population and appear to be over-transmitted compared to others known for their high rate of cervical cancer (Alsbeih et al., 2017). This has further confirmed the results and forward the combination of relative low rate of HPV infection, over-transmission of protective TP53 genetic variant proline along with societal variables as the rationale behind the low incidence of cervical cancer in Saudi women and probably in the region of western Asia. This conclusion has impact on personalized preventive medicine where genetic makeup of the patients can increase or decrease the risk of developing cervical cancer. This also emphasizes the importance of screening years before cancer development. Thus, to gauge the risk of cervical cancer in women under surveillance for this eventuality, women with abnormal cervical cytology who have the combination of high risk HPV infection and genetic predisposition would require more attention and closer follow up to prevent malignant transformation.

Funding Statement

The study was supported by the National Science, Technology and Innovation Plan (King Abdulaziz City for Science and Technology) grant 12-MED2945-20 (RAC no. 2060 029, 2130 025).
  29 in total

1.  Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.

Authors:  A Storey; M Thomas; A Kalita; C Harwood; D Gardiol; F Mantovani; J Breuer; I M Leigh; G Matlashewski; L Banks
Journal:  Nature       Date:  1998-05-21       Impact factor: 49.962

Review 2.  Human papillomaviruses-related cancers. Presence and prevention strategies in the Middle east and north African regions.

Authors:  Ala-Eddin Al Moustafa; Rana Al-Awadhi; Nabiha Missaoui; Ishag Adam; Raika Durusoy; Lina Ghabreau; Nizar Akil; Hussain Gadelkarim Ahmed; Amber Yasmeen; Ghazi Alsbeih
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

Authors:  Silvia de Sanjose; Wim Gv Quint; Laia Alemany; Daan T Geraets; Jo Ellen Klaustermeier; Belen Lloveras; Sara Tous; Ana Felix; Luis Eduardo Bravo; Hai-Rim Shin; Carlos S Vallejos; Patricia Alonso de Ruiz; Marcus Aurelho Lima; Nuria Guimera; Omar Clavero; Maria Alejo; Antonio Llombart-Bosch; Chou Cheng-Yang; Silvio Alejandro Tatti; Elena Kasamatsu; Ermina Iljazovic; Michael Odida; Rodrigo Prado; Muhieddine Seoud; Magdalena Grce; Alp Usubutun; Asha Jain; Gustavo Adolfo Hernandez Suarez; Luis Estuardo Lombardi; Aekunbiola Banjo; Clara Menéndez; Efrén Javier Domingo; Julio Velasco; Ashrafun Nessa; Saibua C Bunnag Chichareon; You Lin Qiao; Enrique Lerma; Suzanne M Garland; Toshiyuki Sasagawa; Annabelle Ferrera; Doudja Hammouda; Luciano Mariani; Adela Pelayo; Ivo Steiner; Esther Oliva; Chris Jlm Meijer; Waleed Fahad Al-Jassar; Eugenia Cruz; Thomas C Wright; Ana Puras; Cecilia Ladines Llave; Maria Tzardi; Theodoros Agorastos; Victoria Garcia-Barriola; Christine Clavel; Jaume Ordi; Miguel Andújar; Xavier Castellsagué; Gloria I Sánchez; Andrzej Marcin Nowakowski; Jacob Bornstein; Nubia Muñoz; F Xavier Bosch
Journal:  Lancet Oncol       Date:  2010-10-15       Impact factor: 41.316

Review 4.  The epidemiology of human papillomavirus infections.

Authors:  Janet G Baseman; Laura A Koutsky
Journal:  J Clin Virol       Date:  2005-03       Impact factor: 3.168

5.  Cancer incidence in Tehran metropolis: the first report from the Tehran Population-based Cancer Registry, 1998-2001.

Authors:  Mohammad-Ali Mohagheghi; Alireza Mosavi-Jarrahi; Reza Malekzadeh; Max Parkin
Journal:  Arch Iran Med       Date:  2009-01       Impact factor: 1.354

6.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

7.  Cancer incidence in egypt: results of the national population-based cancer registry program.

Authors:  Amal S Ibrahim; Hussein M Khaled; Nabiel Nh Mikhail; Hoda Baraka; Hossam Kamel
Journal:  J Cancer Epidemiol       Date:  2014-09-21

8.  Cancer Incidence in Saudi Arabia: 2012 Data from the Saudi Cancer Registry

Authors:  Shouki Bazarbashi; Haya Al Eid; Joan Minguet
Journal:  Asian Pac J Cancer Prev       Date:  2017-09-27

9.  Reduced rate of human papillomavirus infection and genetic overtransmission of TP53 72C polymorphic variant lower cervical cancer incidence.

Authors:  Ghazi A Alsbeih; Najla M Al-Harbi; Sara S Bin Judia; Hatim A Khoja; Mohamed M Shoukri; Asma M Tulbah
Journal:  Cancer       Date:  2017-04-10       Impact factor: 6.860

10.  Common genetic variants and risk for HPV persistence and progression to cervical cancer.

Authors:  Sophia S Wang; Paula Gonzalez; Kai Yu; Carolina Porras; Qizhai Li; Mahboobeh Safaeian; Ana Cecilia Rodriguez; Mark E Sherman; Concepcion Bratti; Mark Schiffman; Sholom Wacholder; Robert D Burk; Rolando Herrero; Stephen J Chanock; Allan Hildesheim
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more
  3 in total

1.  Prevalence of Human Papillomavirus (HPV) Infection and the Association with Survival in Saudi Patients with Head and Neck Squamous Cell Carcinoma.

Authors:  Ghazi Alsbeih; Najla Al-Harbi; Sara Bin Judia; Wejdan Al-Qahtani; Hatim Khoja; Medhat El-Sebaie; Asma Tulbah
Journal:  Cancers (Basel)       Date:  2019-06-13       Impact factor: 6.639

2.  Silencing of KCNA1 suppresses the cervical cancer development via mitochondria damage.

Authors:  Li Liu; Yumei Chen; Qingyuan Zhang; Changzhong Li
Journal:  Channels (Austin)       Date:  2019-12       Impact factor: 2.581

3.  The quality-adjusted life-years in the oncological patients' health-related quality of life.

Authors:  Karolina Kucnerowicz; Agata Pietrzak; Witold Cholewiński; Piotr Martenka; Andrzej Marszałek; Ewa Burchardt; Erwin Strzesak
Journal:  Sci Rep       Date:  2022-08-09       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.